Literature DB >> 12610305

EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin.

Yukako Oda1, Nobuko Hosokawa, Ikuo Wada, Kazuhiro Nagata.   

Abstract

Terminally misfolded proteins in the endoplasmic reticulum (ER) are retrotranslocated to the cytoplasm and degraded by proteasomes through a mechanism known as ER-associated degradation (ERAD). EDEM, a postulated Man8B-binding protein, accelerates the degradation of misfolded proteins in the ER. Here, EDEM was shown to interact with calnexin, but not with calreticulin, through its transmembrane region. Both binding of substrates to calnexin and their release from calnexin were required for ERAD to occur. Overexpression of EDEM accelerated ERAD by promoting the release of terminally misfolded proteins from calnexin. Thus, EDEM appeared to function in the ERAD pathway by accepting substrates from calnexin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610305     DOI: 10.1126/science.1079181

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  144 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  BAP31 and BiP are essential for dislocation of SV40 from the endoplasmic reticulum to the cytosol.

Authors:  Roger Geiger; Daniel Andritschke; Sarah Friebe; Fabian Herzog; Stefania Luisoni; Thomas Heger; Ari Helenius
Journal:  Nat Cell Biol       Date:  2011-09-25       Impact factor: 28.824

Review 3.  Redox-Mediated Regulatory Mechanisms of Endoplasmic Reticulum Homeostasis.

Authors:  Ryo Ushioda; Kazuhiro Nagata
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-05-01       Impact factor: 10.005

4.  Regulation of nicotinic receptor expression by the ubiquitin-proteasome system.

Authors:  John C Christianson; William N Green
Journal:  EMBO J       Date:  2004-10-14       Impact factor: 11.598

5.  Novel mannosidase inhibitors probe glycoprotein degradation pathways in cells.

Authors:  Terry D Butters; Dominic S Alonzi; Nikolay V Kukushkin; Yuan Ren; Yves Blériot
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

6.  Delta F508 CFTR pool in the endoplasmic reticulum is increased by calnexin overexpression.

Authors:  Tsukasa Okiyoneda; Kazutsune Harada; Motohiro Takeya; Kaori Yamahira; Ikuo Wada; Tsuyoshi Shuto; Mary Ann Suico; Yasuaki Hashimoto; Hirofumi Kai
Journal:  Mol Biol Cell       Date:  2003-10-31       Impact factor: 4.138

7.  Redox-assisted regulation of Ca2+ homeostasis in the endoplasmic reticulum by disulfide reductase ERdj5.

Authors:  Ryo Ushioda; Akitoshi Miyamoto; Michio Inoue; Satoshi Watanabe; Masaki Okumura; Ken-Ichi Maegawa; Kaiku Uegaki; Shohei Fujii; Yasuko Fukuda; Masataka Umitsu; Junichi Takagi; Kenji Inaba; Katsuhiko Mikoshiba; Kazuhiro Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-30       Impact factor: 11.205

8.  Posttranscriptional Regulation of Glycoprotein Quality Control in the Endoplasmic Reticulum Is Controlled by the E2 Ub-Conjugating Enzyme UBC6e.

Authors:  Masatoshi Hagiwara; Jingjing Ling; Paul-Albert Koenig; Hidde L Ploegh
Journal:  Mol Cell       Date:  2016-08-25       Impact factor: 17.970

9.  Characterization of Schizosaccharomyces pombe ER alpha-mannosidase: a reevaluation of the role of the enzyme on ER-associated degradation.

Authors:  Federico Movsichoff; Olga A Castro; Armando J Parodi
Journal:  Mol Biol Cell       Date:  2005-08-03       Impact factor: 4.138

10.  ER-to-lysosome-associated degradation of proteasome-resistant ATZ polymers occurs via receptor-mediated vesicular transport.

Authors:  Ilaria Fregno; Elisa Fasana; Timothy J Bergmann; Andrea Raimondi; Marisa Loi; Tatiana Soldà; Carmela Galli; Rocco D'Antuono; Diego Morone; Alberto Danieli; Paolo Paganetti; Eelco van Anken; Maurizio Molinari
Journal:  EMBO J       Date:  2018-08-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.